Volition Sponsors Symposium on Nu.Q NETs Plasma Biomarker for Hidradenitis Suppurativa Treatment

VolitionRx Limited sponsors a symposium at the European Hidradenitis Suppurativa Foundation Conference to present data on its Nu.Q® NETs assay in patient management for Hidradenitis Suppurativa. The assay can classify patients and guide treatment selection and modification. The study demonstrates the potential of Nu.Q® NETs as a biomarker for ongoing and future clinical studies, aiming to guide treatment initiation and cessation. The market opportunity for such indications is significant, with a Total Addressable Market of $3.8 billion.